Experimental cell therapy targets rare Muscle-Weakening disease
Disease control
Completed
This early-stage study tested a new cell therapy called MuSK-CAART in 7 people with a rare, severe form of myasthenia gravis (MuSK MG). The treatment uses a patient's own immune cells, modified to attack the harmful antibodies causing the disease. The main goal was to check safet…
Phase: PHASE1 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC